- Title
- GOG-3119/ENGOT-en29/TroFuse-033: A phase 3, randomized study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
- Creators
- Bradley Monk - Gynecologic Oncology GroupJerome Alexandre - Université Paris CitéLuis Manso Sánchez - Hospital Universitario 12 De OctubreElena Ioana Braicu - Charité - Universitätsmedizin BerlinRadoslaw Madry - PGOG, Uniwersytet Medyczny im K. Marcinkowskiego w Poznaniu, Poznan, PolandAntoinetta J.M. Beijers - Maastricht UniversityAlberto Farolfi - MITO and IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, ItalyChristof Vulsteke - University of AntwerpKosei Hasegawa - Saitama Medical UniversityJian-Liu Wang - Peking University People's Hospitalet al.
- Publication Details
- Gynecologic oncology, Vol.208, pp.S103-S104
- Publisher
- Elsevier Inc
- Identifiers
- 991006271904302656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
GOG-3119/ENGOT-en29/TroFuse-033: A phase 3, randomized study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
Gynecologic oncology, Vol.208, pp.S103-S104
05/2026
Metrics
1 Record Views